Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 3Phase 1/2 2Phase 3 1

Status

Withdrawn 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 416Radiotherapy 276fludarabine 238Gemcitabine 211Cisplatin 203Nivolumab 184pembrolizumab 183Paclitaxel 176Carboplatin 168Magnetic Resonance Spectroscopy 166fludarabine phosphate 156Irinotecan 135Bevacizumab 133Cytarabine 128Specimen Handling 124Capecitabine 124Temozolomide 123Radiosurgery 118Docetaxel 116Biopsy 116Ipilimumab 113Dexamethasone 113Radiation 111Oxaliplatin 110Fluorouracil 110Rituximab 108Etoposide 108Filgrastim 99Lenalidomide 98Everolimus 96

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × tepotinib × Clear all
NCT07619339 2026-06-02

A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Recruiting
16 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05782361 2026-04-24

POTENT

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
19 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05120960 2024-04-17

A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors

M.D. Anderson Cancer Center

Phase 1 Withdrawn
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡